Art. -Nr.: HY-N0020

Echinacoside

21 Cited Publications

Kundenbewertung

Based on 21 publication(s) in Google Scholar

Echinacoside, one of the phenylethanoids isolated from the stems of Cistanche deserticola, effectively inhibits Wnt/β-catenin signaling. Echinacoside elicits neuroprotection by activating Trk receptors and their downstream signal pathways. Antiosteoporotic activity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.71%
CAS. Nr.: 82854-37-3
Formel: C₃₅H₄₆O₂₀
Molecular Weight:786.73

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Echinacoside Chemical Structure

CAS. Nr.: 82854-37-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vivo
- Clinical Trial
Chemical Information
Publications (21)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle Wnt Isoform-spezifische Produkte anzeigen :

In Vivo

Echinacoside (30-270 mg/kg body weight; p.o.; daily for 12 weeks) significantly reverses the increases of body weight, serum hydroxyproline (HOP) levels, and the decreases of uterus wet weight and bone mineral density (BMD) in In ovariectomized (OVX) rats^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Fifty-six aged 6 months female Sprague-Dawley rats (OVX rat model)^[3]
Dosage:

30, 90, 270 mg/kg body weight
Administration:

p.o.; daily for 12 weeks
Result:

The increases of body weight, serum hydroxyproline (HOP) levels, and the decreases of uterus wet weight and BMD were significantly reversed.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 82854-37-3
Appearance Solid
Molecular Weight 786.73
Formel C₃₅H₄₆O₂₀
Color White to yellow
SMILES

OC1=CC(/C=C/C(O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@H](OCCC4=CC(O)=C(O)C=C4)O[C@@H]2CO[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)=O)=CC=C1O
Structure Classification
- Phenylpropanoids
- Simple Phenylpropanols
- Phenols
- Polyphenols
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (21)

All Cell Proliferation/Viability AssayIn Vivo Efficacy StudyIHCWB

Sort by:

Journal Impact Factor

Gut

Galectin-4 drives anti-PD-L1/BVZ resistance by regulating metabolic adaptation and tumour-associated neutrophils in hepatocellular carcinoma. [Abstract]

2025 Oct 7:gutjnl-2025-336374. PMID: 41057233

Echinacoside purchased from MedChemExpress. Usage Cited in: Gut. 2025 Oct 7:gutjnl-2025-336374. [Abstract]

Cell viability of (A) HepG2 and (B) LO2 cells incubated with different concentrations of Echinacoside ( ECH; 0, 1, 2, 5, 10, or 20 μg/mL) for 0, 12, 24, and 48 h.

Echinacoside purchased from MedChemExpress. Usage Cited in: Gut. 2025 Oct 7:gutjnl-2025-336374. [Abstract]

HepG2 cell survival and tumor volume. Xenograft mice 4 weeks (4-week-old BALB/c nude mice; HepG2 cells ) post-injection with Echinacoside (ECH; 5 mg/kg/day; i.v.), AMPG (5 mg/kg/day), or ECH@AMPG (5 mg/kg/day) after tumor formation for 1 week for 4 weeks.

Echinacoside purchased from MedChemExpress. Usage Cited in: Gut. 2025 Oct 7:gutjnl-2025-336374. [Abstract]

TUNEL analysis showed increased HepG2 cell apoptosis in ECH-treated mice. Xenograft mice 4 weeks (4-week-old BALB/c nude mice; HepG2 cells ) post-injection with Echinacoside (ECH; 5 mg/kg/day; i.v.), AMPG (5 mg/kg/day), or ECH@AMPG (5 mg/kg/day) after tumor formation for 1 week for 4 weeks.

Echinacoside purchased from MedChemExpress. Usage Cited in: Gut. 2025 Oct 7:gutjnl-2025-336374. [Abstract]

Xenograft mouse tumors showing UBR5, AXIN1, LDHA, PKM2, Survivin, C-myc, and β-catenin expression. Xenograft mice 4 weeks (4-week-old BALB/c nude mice; HepG2 cells ) post-injection with Echinacoside (ECH; 5 mg/kg/day; i.v.), AMPG (5 mg/kg/day), or ECH@AMPG (5 mg/kg/day) after tumor formation for 1 week for 4 weeks.
Autophagy

XIAP-ULK1-Mediated mitophagy modulates carnitine metabolism to mitigate diabetic kidney disease. [Abstract]

2025 Oct 25. PMID: 41139215
Cell Mol Biol Lett

Targeting UBR5 in hepatocellular carcinoma cells and precise treatment via echinacoside nanodelivery. [Abstract]

2022 Oct 12;27(1):92. PMID: 36224534
Phytomedicine

Echinacoside modulates PARP14-GLUD1 axis to mediate energy metabolism reprogramming and mitochondrial function in diminished ovarian reserve. [Abstract]

2026 Jun:155:158100. PMID: 41895093
Phytomedicine

Cistanche deserticola extract and its active components, echinacoside, ameliorate sarcopenia by activating the IGF-1/PI3K-AKT pathway to modulate ferroptosis. [Abstract]

2025 Nov 25:148:157378. PMID: 41106096
Free Radic Biol Med

Echinacoside improves antioxidant responses and angiogenesis through Parkin-MFN2-mediated mitophagy to promote diabetic wound healing. [Abstract]

2026 Jul:250:436-452. PMID: 41962601
Cell Prolif

Revitalising Aging Oocytes: Echinacoside Restores Mitochondrial Function and Cellular Homeostasis Through Targeting GJA1/SIRT1 Pathway. [Abstract]

2025 Oct;58(10):e70044. PMID: 40251808
Eur J Pharmacol

Echinacoside mitigates sepsis-associated encephalopathy by inhibiting STING pathway and reducing neuroinflammation. [Abstract]

2025 Oct 15:1005:178092. PMID: 40885235
Int Immunopharmacol

Echinacoside ameliorates 5-fluorouracil-induced endothelial injury and senescence through SIRT1 activation. [Abstract]

2023 Jul:120:110279. PMID: 37187128
J Cell Mol Med

Echinacoside inhibited cardiomyocyte pyroptosis and improved heart function of HF rats induced by isoproterenol via suppressing NADPH/ROS/ER stress. [Abstract]

2022 Nov;26(21):5414-5425. PMID: 36201630
J Cell Mol Med

Echinacoside reverses myocardial remodeling and improves heart function via regulating SIRT1/FOXO3a/MnSOD axis in HF rats induced by isoproterenol. [Abstract]

2021 Jan;25(1):203-216. PMID: 33314649
Naunyn Schmiedebergs Arch Pharmacol

Echinacoside activates Nrf2/PPARγ signaling pathway to modulate mitochondrial fusion-fission balance to ameliorate ox-LDL-induced dysfunction of coronary artery endothelial cells. [Abstract]

2024 Dec;397(12):9767-9776. PMID: 38916831
Neurotox Res

Tubuloside B Alleviates Aβ25-35 Induced PC12 Cell Injury by Attenuating Pyroptosis, Apoptosis and Excessive Autophagy. [Abstract]

2026 Mar 19;44(2):12. PMID: 41854817
Biochim Biophys Acta Mol Cell Biol Lipids

Echinacoside suppresses macrophage lipid accumulation and attenuates atherosclerosis via the MDM2/PPARγ/ABCA1 signaling axis. [Abstract]

2025 Oct;1870(7):159681. PMID: 40819820
Chem Biol Drug Des

Echinacoside Alleviates Carbon Tetrachloride-Induced Chronic Liver Injury by Modulating the NF-κB/NLRP3 Inflammasome Pathway. [Abstract]

2024 Sep;104(3):e14616. PMID: 39245793
Immunopharmacol Immunotoxicol

Echinacoside alleviates osteoarthritis in rats by activating the Nrf2-HO-1 signaling pathway. [Abstract]

2022 Dec;44(6):850-859. PMID: 35815581
J Neurosci Res

Enhanced mitochondrial inhibition by 3,4-dihydroxyphenyl-acetaldehyde (DOPAL)-oligomerized α-synuclein. [Abstract]

2019 Dec;97(12):1689-1705. PMID: 31420910
PeerJ

The role of echinacoside-based cross-linker nanoparticles in the treatment of osteoporosis. [Abstract]

2024 Apr 9:12:e17229. PMID: 38618561
J Mol Histol

Echinacoside ameliorates bleomycin-induced idiopathic pulmonary fibrosis by regulating macrophage polarization. [Abstract]

2025 Nov 24;57(1):4. PMID: 41284091
Biochem Biophys Res Commun

Echinacoside inhibits breast cancer cells by suppressing the Wnt/β-catenin signaling pathway. [Abstract]

2020 May 21;526(1):170-175. PMID: 32201078

Echinacoside purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2020 May 21;526(1):170-175. [Abstract]

Echinacoside inhibits the expression of key Wnt/b-catenin proteins in breast cancer cell lines. MDA-MB-231 and MDA-MB-468 cells are treated with the indicated concentrations of Echinacoside for 24 h. Cells are harvested, and proteins are extracted using RIPA cell lysis buffer.

Echinacoside purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2020 May 21;526(1):170-175. [Abstract]

Echinacoside inhibits the expression of key Wnt/b-catenin proteins in breast cancer cell lines. MDA-MB-231 and MDA-MB-468 cells are treated with the indicated concentrations of Echinacoside for 24 h. LEF1, CD44, and cyclin D1 protein expression levels are detected by western blot.
SSRN

2026 Mar 20.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (127.11 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 35.71 mg/mL (45.39 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.2711 mL

6.3554 mL

12.7108 mL

5 mM

0.2542 mL

1.2711 mL

2.5422 mL

10 mM

0.1271 mL

0.6355 mL

1.2711 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (3.18 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (3.18 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (3.18 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 100 mg/mL (127.11 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Li X, et al. Echinacoside ameliorates D-galactosamine plus lipopolysaccharide-induced acute liver injury in mice via inhibition of apoptosis and inflammation. Scand J Gastroenterol. 2014 Aug;49(8):993-1000. [Content Brief]

[2]. Tang C, et al. Echinacoside inhibits breast cancer cells by suppressing the Wnt/β-catenin signaling pathway. Biochem Biophys Res Commun. 2020 Mar 19. pii: S0006-291X(20)30530-1. [Content Brief]

[3]. Li F, et al. Antiosteoporotic activity of echinacoside in ovariectomized rats. Phytomedicine. 2013 Apr 15;20(6):549-57. [Content Brief]

[4]. Zhang D, et al. Echinacoside inhibits amyloid fibrillization of HEWL and protects against Aβ-induced neurotoxicity. Int J Biol Macromol. 2014 Sep 2;72C:243-253. [Content Brief]

[5]. Zhu M, et al. Transient exposure to echinacoside is sufficient to activate Trk signaling and protect neuronal cells from rotenone. J Neurochem. 2013 Feb;124(4):571-80. [Content Brief]

[6]. Li F, et al. Echinacoside promotes bone regeneration by increasing OPG/RANKL ratio in MC3T3-E1 cells. Fitoterapia. 2012 Dec;83(8):1443-50. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	1.2711 mL	6.3554 mL	12.7108 mL	31.7771 mL
	5 mM	0.2542 mL	1.2711 mL	2.5422 mL	6.3554 mL
	10 mM	0.1271 mL	0.6355 mL	1.2711 mL	3.1777 mL
	15 mM	0.0847 mL	0.4237 mL	0.8474 mL	2.1185 mL
	20 mM	0.0636 mL	0.3178 mL	0.6355 mL	1.5889 mL
	25 mM	0.0508 mL	0.2542 mL	0.5084 mL	1.2711 mL
	30 mM	0.0424 mL	0.2118 mL	0.4237 mL	1.0592 mL
	40 mM	0.0318 mL	0.1589 mL	0.3178 mL	0.7944 mL
DMSO	50 mM	0.0254 mL	0.1271 mL	0.2542 mL	0.6355 mL
	60 mM	0.0212 mL	0.1059 mL	0.2118 mL	0.5296 mL
	80 mM	0.0159 mL	0.0794 mL	0.1589 mL	0.3972 mL
	100 mM	0.0127 mL	0.0636 mL	0.1271 mL	0.3178 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Echinacoside

21 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Echinacoside

Differentiation Inducing Compound Library

Glycoside Compound Library

Anti-Cardiovascular Disease Compound Library

Medicine Food Homology Compound Library

Phenols Library

Cytoskeleton Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Antihypertensive Compound Library

Extracellular Vesicles (EVs) Compound Library

Bioactive Compound Library Max

Natural Product Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Anti-Aging Compound Library Mini

Natural Product and Natural Product-Like Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Natural Product Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Publications Citing Use of MedChemExpress (MCE) Echinacoside

Alle Wnt Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (21)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Echinacoside Related Classifications

HY-N0020 Related Classifications